STOCK TITAN

[Form 4] ACM Research, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

ACM Research (ACMR) Form 4: CEO, President and Director David H. Wang reported vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025, from a 2020 performance grant. These options are now exercisable and expire on March 19, 2030.

The vesting occurred after the company’s market capitalization reached $2,553,383,586 under the grant’s formula; remaining tranches vest if market cap reaches $3,553,383,586. Indirect beneficial holdings disclosed include 620,001 shares (Wang‑Chen Family Living Trust), 180,000 (Family Irrevocable Trust for Wang Children), 100,002 (spouse), and 45,837 (daughter).

ACM Research (ACMR) Modulo 4: il CEO, Presidente e Direttore David H. Wang ha riportato la maturazione e l'acquisizione di 545.400 opzioni azionarie al prezzo di esercizio di $7,36 in data 27 ottobre 2025, relative a una concessione di performance del 2020. Queste opzioni sono ora esercitabili e scadono il 19 marzo 2030.

La maturazione è avvenuta dopo che la capitalizzazione di mercato della società ha raggiunto $2.553.383.586 secondo la formula della concessione; le tranche residue matureranno se la capitalizzazione raggiungerà $3.553.383.586. Le partecipazioni indirette beneficiarie indicate includono 620.001 azioni (Wang‑Chen Family Living Trust), 180.000 (Family Irrevocable Trust for Wang Children), 100.002 (coniuge) e 45.837 (figlia).

ACM Research (ACMR) Formulario 4: el CEO, Presidente y Director David H. Wang reportó la consolidación y adquisición de 545.400 opciones sobre acciones a un precio de ejercicio de $7,36 el 27 de octubre de 2025, procedentes de una asignación de rendimiento de 2020. Estas opciones son ahora exercitables y expiran el 19 de marzo de 2030.

La consolidación ocurrió después de que la capitalización de mercado de la empresa alcanzara $2.553.383.586 según la fórmula de la asignación; las tranches restantes se consolidarán si la capitalización alcanza $3.553.383.586. Las participaciones indirectas beneficiosas divulgadas incluyen 620.001 acciones (Wang‑Chen Family Living Trust), 180.000 (Family Irrevocable Trust for Wang Children), 100.002 (cónyuge) y 45.837 (hija).

ACM Research (ACMR) Form 4: CEO, President 및 이사인 David H. Wang은 545,400주 옵션을 행사 가격 $7.36으로 2025년 10월 27일에 취득 및 획득했다고 보고했습니다. 이는 2020년 성과 보조금에서 비롯된 것입니다. 이 옵션은 이제 행사가 가능하며 2030년 3월 19일에 만료됩니다.

이번 취득은 보조금 공식에 따른 시가총액이 $2,553,383,586에 도달한 뒤에 이루어졌으며, 남은 트랜치들은 시가총액이 $3,553,383,586에 도달하면 취득됩니다. 간접적 수혜 보유는 620,001 주(Wang‑Chen Family Living Trust), 180,000 (Wang Children를 위한 Family Irrevocable Trust), 100,002 (배우자), 45,837 (딸)을 포함해 공시되었습니다.

ACM Research (ACMR) Formulaire 4 : le PDG, Président et Directeur David H. Wang a déclaré l'acquisition et l'acquisition de 545 400 options d'achat d'actions à un prix d'exercice de $7,36 le 27 octobre 2025, provenant d'une attribution de performance de 2020. Ces options sont désormais exerçables et expirent le 19 mars 2030.

L'acquisition a eu lieu après que la capitalisation boursière de l'entreprise ait atteint $2 553 383 586 selon la formule de la subvention; les tranches restantes vestent si la capitalisation atteint $3 553 383 586. Les avoirs bénéficiaires indirects divulgués comprennent 620 001 actions (Wang‑Chen Family Living Trust), 180 000 (Family Irrevocable Trust for Wang Children), 100 002 (conjoint) et 45 837 (fille).

ACM Research (ACMR) Formular 4: CEO, Präsident und Direktor David H. Wang meldete die Vesting und den Erwerb von 545.400 Aktienoptionen zu einem Ausübungspreis von $7,36 am 27. Oktober 2025, aus einer Leistungszuwendung von 2020. Diese Optionen sind jetzt ausübbar und laufen am 19. März 2030 ab.

Die Vesting erfolgte, nachdem die Marktkapitalisierung des Unternehmens gemäß der Garantieformel $2.553.383.586 erreicht habe; verbleibende Tranchen vesten, falls die Marktkapitalisierung $3.553.383.586 erreicht. Indirekte begünstigte Beteiligungen, die offengelegt wurden, umfassen 620.001 Aktien (Wang‑Chen Family Living Trust), 180.000 (Family Irrevocable Trust for Wang Children), 100.002 (Ehepartner) und 45.837 (Tochter).

تقرير ACM Research (ACMR) النموذج 4: أبلغ الرئيس التنفيذي، والرئيس والمدير ديفيد ه. وانغ عن انخراط وتملك 545,400 خياراً لسهم بسعر تمارين قدره $7.36 في 27 أكتوبر 2025، من منحة أداء لعام 2020. هذه الخيارات أصبحت قابلة للتمرين وتنتهي صلاحيتها في 19 مارس 2030.

حدث الانخراط بعد أن وصلت القيمة السوقية للشركة إلى $2,553,383,586 وفق صيغة المنحة؛ تتوجب أن تستحق الدفعات المتبقية إذا وصلت القيمة السوقية إلى $3,553,383,586. تشمل الحيازات المستفيدة غير المباشرة المعلنة 620,001 سهم (Wang‑Chen Family Living Trust)، 180,000 (Family Irrevocable Trust for Wang Children)، 100,002 (الزوج/الزوجة)، و45,837 (الابنة).

Positive
  • None.
Negative
  • None.

ACM Research (ACMR) Modulo 4: il CEO, Presidente e Direttore David H. Wang ha riportato la maturazione e l'acquisizione di 545.400 opzioni azionarie al prezzo di esercizio di $7,36 in data 27 ottobre 2025, relative a una concessione di performance del 2020. Queste opzioni sono ora esercitabili e scadono il 19 marzo 2030.

La maturazione è avvenuta dopo che la capitalizzazione di mercato della società ha raggiunto $2.553.383.586 secondo la formula della concessione; le tranche residue matureranno se la capitalizzazione raggiungerà $3.553.383.586. Le partecipazioni indirette beneficiarie indicate includono 620.001 azioni (Wang‑Chen Family Living Trust), 180.000 (Family Irrevocable Trust for Wang Children), 100.002 (coniuge) e 45.837 (figlia).

ACM Research (ACMR) Formulario 4: el CEO, Presidente y Director David H. Wang reportó la consolidación y adquisición de 545.400 opciones sobre acciones a un precio de ejercicio de $7,36 el 27 de octubre de 2025, procedentes de una asignación de rendimiento de 2020. Estas opciones son ahora exercitables y expiran el 19 de marzo de 2030.

La consolidación ocurrió después de que la capitalización de mercado de la empresa alcanzara $2.553.383.586 según la fórmula de la asignación; las tranches restantes se consolidarán si la capitalización alcanza $3.553.383.586. Las participaciones indirectas beneficiosas divulgadas incluyen 620.001 acciones (Wang‑Chen Family Living Trust), 180.000 (Family Irrevocable Trust for Wang Children), 100.002 (cónyuge) y 45.837 (hija).

ACM Research (ACMR) Form 4: CEO, President 및 이사인 David H. Wang은 545,400주 옵션을 행사 가격 $7.36으로 2025년 10월 27일에 취득 및 획득했다고 보고했습니다. 이는 2020년 성과 보조금에서 비롯된 것입니다. 이 옵션은 이제 행사가 가능하며 2030년 3월 19일에 만료됩니다.

이번 취득은 보조금 공식에 따른 시가총액이 $2,553,383,586에 도달한 뒤에 이루어졌으며, 남은 트랜치들은 시가총액이 $3,553,383,586에 도달하면 취득됩니다. 간접적 수혜 보유는 620,001 주(Wang‑Chen Family Living Trust), 180,000 (Wang Children를 위한 Family Irrevocable Trust), 100,002 (배우자), 45,837 (딸)을 포함해 공시되었습니다.

ACM Research (ACMR) Formulaire 4 : le PDG, Président et Directeur David H. Wang a déclaré l'acquisition et l'acquisition de 545 400 options d'achat d'actions à un prix d'exercice de $7,36 le 27 octobre 2025, provenant d'une attribution de performance de 2020. Ces options sont désormais exerçables et expirent le 19 mars 2030.

L'acquisition a eu lieu après que la capitalisation boursière de l'entreprise ait atteint $2 553 383 586 selon la formule de la subvention; les tranches restantes vestent si la capitalisation atteint $3 553 383 586. Les avoirs bénéficiaires indirects divulgués comprennent 620 001 actions (Wang‑Chen Family Living Trust), 180 000 (Family Irrevocable Trust for Wang Children), 100 002 (conjoint) et 45 837 (fille).

ACM Research (ACMR) Formular 4: CEO, Präsident und Direktor David H. Wang meldete die Vesting und den Erwerb von 545.400 Aktienoptionen zu einem Ausübungspreis von $7,36 am 27. Oktober 2025, aus einer Leistungszuwendung von 2020. Diese Optionen sind jetzt ausübbar und laufen am 19. März 2030 ab.

Die Vesting erfolgte, nachdem die Marktkapitalisierung des Unternehmens gemäß der Garantieformel $2.553.383.586 erreicht habe; verbleibende Tranchen vesten, falls die Marktkapitalisierung $3.553.383.586 erreicht. Indirekte begünstigte Beteiligungen, die offengelegt wurden, umfassen 620.001 Aktien (Wang‑Chen Family Living Trust), 180.000 (Family Irrevocable Trust for Wang Children), 100.002 (Ehepartner) und 45.837 (Tochter).

تقرير ACM Research (ACMR) النموذج 4: أبلغ الرئيس التنفيذي، والرئيس والمدير ديفيد ه. وانغ عن انخراط وتملك 545,400 خياراً لسهم بسعر تمارين قدره $7.36 في 27 أكتوبر 2025، من منحة أداء لعام 2020. هذه الخيارات أصبحت قابلة للتمرين وتنتهي صلاحيتها في 19 مارس 2030.

حدث الانخراط بعد أن وصلت القيمة السوقية للشركة إلى $2,553,383,586 وفق صيغة المنحة؛ تتوجب أن تستحق الدفعات المتبقية إذا وصلت القيمة السوقية إلى $3,553,383,586. تشمل الحيازات المستفيدة غير المباشرة المعلنة 620,001 سهم (Wang‑Chen Family Living Trust)، 180,000 (Family Irrevocable Trust for Wang Children)، 100,002 (الزوج/الزوجة)، و45,837 (الابنة).

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang David H

(Last) (First) (Middle)
C/O ACM RESEARCH, INC.
42307 OSGOOD ROAD, SUITE I

(Street)
FREMONT CA 94539

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACM Research, Inc. [ ACMR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 100,002 I By Jing Chen, wife of David H. Wang
Class A Common Stock 45,837 I By Sophia Wang, daughter of David H. Wang
Class A Common Stock 180,000 I By David Hui Wang and Jing Chen Family Irrevocable Trust for Wang Children
Class A Common Stock 620,001 I By Wang-Chen Family Living Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $7.36 10/27/2025 A 545,400 (1)(2) 03/19/2030 Class A Common Stock 545,400 $0 545,400 D
Explanation of Responses:
1. On March 20, 2020, the reporting person was granted options to purchase an aggregate of 1,636,197 shares of the Issuer's Class A common stock, based on the satisfaction of certain performance criteria. In general, one-third of the shares subject to the options vest and become exercisable upon an increase in the Issuer's market capitalization (calculated as described in footnote 2) of $1 billion, $2 billion and $3 billion, respectively, from the market capitalization of $553,383,586 on the date of grant. 545,400 shares vested and became exercisable on October 27, 2025, which was the first trading day as of which the Issuer's market capitalization equaled or exceeded $2,553,383,586. The remaining shares will vest and become exercise upon the first trading days, if any, on which the Issuer's market capitalization equals or exceeds $3,553,383,586.
2. For purposes of the options, the market capitalization as of a specified trading day is calculated by multiplying (a) the average of the daily volume-weighted average price per share of the Issuer's Class A common stock for each of the trading days occurring during the thirty calendar day period ending on that specified trading day by (b) the total number of issued and outstanding shares of the Issuer's Class A and Class B common stock as of 11:59 p.m. (Eastern time) on such specified trading day.
Remarks:
Chief Executive Officer, President and Director
/s/ Mark McKechnie, Attorney-in-Fact for David H. Wang 10/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ACMR disclose on this Form 4?

David H. Wang reported the vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025.

What triggered the 545,400 options to vest for ACMR’s CEO?

Vesting occurred when market capitalization reached $2,553,383,586, as defined in the grant’s calculation method.

When do these ACMR options expire?

The options expire on March 19, 2030.

What remains to vest under the 2020 performance grant?

Remaining shares vest upon the first trading day the market capitalization equals or exceeds $3,553,383,586.

What indirect ACMR share holdings were reported?

Reported indirect holdings: 620,001 (Wang‑Chen Family Living Trust), 180,000 (Family Irrevocable Trust for Wang Children), 100,002 (spouse), 45,837 (daughter).

What is the origin of the ACMR option grant?

The options stem from a March 20, 2020 performance grant tied to market capitalization milestones.
Acm Research

NASDAQ:ACMR

ACMR Rankings

ACMR Latest News

ACMR Latest SEC Filings

ACMR Stock Data

2.60B
49.76M
15.04%
70.31%
6.43%
Semiconductor Equipment & Materials
Special Industry Machinery, Nec
Link
United States
FREMONT